Home>
US Stocks>
4d Molecular Therapeutics Inc

4d Molecular Therapeutics Inc share price today

(FDMT)

4d Molecular Therapeutics Inc share price is $7.18 & ₹608.02 as on 10 Dec 2024, 2.30 'hrs' IST

$7.18

▲

-0.17

(-2.31%)

Market is closed - opens 8 PM, 10 Dec 2024

View live 4d Molecular Therapeutics Inc share price in Dollar and Rupees. Guide to invest in 4d Molecular Therapeutics Inc from India. Also see the sentimental analysis on Indian investors investing in 4d Molecular Therapeutics Inc. Get details on the Indian mutual funds that are investing in 4d Molecular Therapeutics Inc. Get Analyst recommendations and forecasts along with all the 4d Molecular Therapeutics Inc's financials.

4d Molecular Therapeutics Inc share price movements

$7.13
$7.58
$7.18
0.7%
Downside
Day's Volatility :5.87%
Upside
5.21%
$6.78
$36.25
$7.18
5.57%
Downside
52 Weeks Volatility :81.3%
Upside
80.19%

4d Molecular Therapeutics Inc Returns

Period	4d Molecular Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-56.03%	-6.4%	0.0%
6 Months	-70.72%	-0.9%	0.0%
1 Year	-52.7%	9.9%	0.0%
3 Years	-69.73%	8.2%	-20.3%

4d Molecular Therapeutics Inc Key Statistics

in dollars & INR

Previous Close	$7.35
Open	$7.35
Today's High	$7.575
Today's Low	$7.13
Market Capitalization	$330.1M
Today's Volume	$481.2K
52 Week High	$36.25
52 Week Low	$6.78
Revenue TTM	$17.0K
EBITDA	$-163.7M
Earnings Per Share (EPS)	$-2.87
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-24.06%

How to invest in 4d Molecular Therapeutics Inc from India?

It is very easy for Indian residents to invest directly in 4d Molecular Therapeutics Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the 4d Molecular Therapeutics Inc stock in both rupees (INR) and dollars (USD). Search for 4d Molecular Therapeutics Inc or FDMT on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of 4d Molecular Therapeutics Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of 4d Molecular Therapeutics Inc shares which would translate to 0.118 fractional shares of 4d Molecular Therapeutics Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards 4d Molecular Therapeutics Inc

-47%

Period: Sep 10, 2024 to Dec 9, 2024. Change in 30 Days versus previous period

Search volume for 4d Molecular Therapeutics Inc on INDmoney from India has reduced in the last 30 days as on Dec 10, 2024. -47% less investors are searching 4d Molecular Therapeutics Inc in the last 30 days versus the previous period.

Global Institutional Holdings in 4d Molecular Therapeutics Inc

Bvf Inc
15.97%
RA Capital Management, LLC
11.03%
BlackRock Inc
10.59%
VR Adviser, LLC
9.52%
Deep Track Capital, LP
8.86%
Goldman Sachs Group Inc
7.77%

Analyst Recommendation on 4d Molecular Therapeutics Inc

Buy

94%Buy

5%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for 4d Molecular Therapeutics Inc(by analysts ranked 0 to 5 stars)

Based on 17 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on 4d Molecular Therapeutics Inc

What analysts predicted

Upside of 535.6%

Current:

$7.18

Target:

$45.64

Insights on 4d Molecular Therapeutics Inc

Price Movement
In the last 7 days, FDMT stock has moved down by -10.1%
Decreasing Revenue
Revenue is down for the last 3 quarters, 28.0K → 3.0K (in $), with an average decrease of 61.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 5 quarters, -10.25M → -43.84M (in $), with an average decrease of 62.1% per quarter
FDMT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 48.1% return, outperforming this stock by 102.5%
FDMT vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 46.0% return, outperforming this stock by 115.2%

4d Molecular Therapeutics Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$14.1M	↑ 144.04%
Net Income	$-9.6M	↓ 14.9%
Net Profit Margin	-67.59%	↑ 126.24%

	FY19	Y/Y Change
Revenue	$7.0M	↓ 50.56%
Net Income	$-52.9M	↑ 454.28%
Net Profit Margin	-757.79%	↓ 690.2%

	FY20	Y/Y Change
Revenue	$13.6M	↑ 94.85%
Net Income	$-56.5M	↑ 6.8%
Net Profit Margin	-415.38%	↑ 342.41%

	FY21	Y/Y Change
Revenue	$18.0M	↑ 32.52%
Net Income	$-68.3M	↑ 20.79%
Net Profit Margin	-378.63%	↑ 36.75%

	FY22	Y/Y Change
Revenue	$3.1M	↓ 82.65%
Net Income	$-101.1M	↑ 47.99%
Net Profit Margin	-3.2K%	↓ 2851.67%

	FY23	Y/Y Change
Revenue	$20.7M	↑ 562.29%
Net Income	$-100.8M	↓ 0.24%
Net Profit Margin	-486.59%	↑ 2743.71%

	Q2 FY23	Q/Q Change
Revenue	$239.0K	↓ 19.8%
Net Income	$-29.6M	↑ 8.65%
Net Profit Margin	-12.4K%	↓ 3244.65%

	Q3 FY23	Q/Q Change
Revenue	$20.2M	↑ 8353.56%
Net Income	$-10.3M	↓ 65.37%
Net Profit Margin	-50.76%	↑ 12340.87%

	Q4 FY23	Q/Q Change
Revenue	$-19.0K	↓ 100.09%
Net Income	$-32.3M	↑ 214.77%
Net Profit Margin	169.9K%	↑ 169961.29%

	Q1 FY24	Q/Q Change
Revenue	$28.0K	↓ 247.37%
Net Income	$-32.4M	↑ 0.37%
Net Profit Margin	-115.7K%	↓ 285628.39%

	Q2 FY24	Q/Q Change
Revenue	$5.0K	↓ 82.14%
Net Income	$-35.0M	↑ 7.88%
Net Profit Margin	-699.1K%	↓ 583342.14%

	Q3 FY24	Q/Q Change
Revenue	$3.0K	↓ 40.0%
Net Income	$-43.8M	↑ 25.43%
Net Profit Margin	-1.5M%	↓ 762373.33%

	FY18	Y/Y Change
Total Assets	$97.0M	↑ 254.94%
Total Liabilities	$124.6M	↑ 165.52%

	FY19	Y/Y Change
Total Assets	$58.2M	↓ 39.95%
Total Liabilities	$131.2M	↑ 5.34%

	FY20	Y/Y Change
Total Assets	$288.3M	↑ 395.12%
Total Liabilities	$31.9M	↓ 75.65%

	FY21	Y/Y Change
Total Assets	$353.5M	↑ 22.6%
Total Liabilities	$560.5M	↑ 1654.58%

	FY22	Y/Y Change
Total Assets	$261.8M	↓ 25.92%
Total Liabilities	$30.5M	↓ 94.56%

	FY23	Y/Y Change
Total Assets	$339.9M	↑ 29.81%
Total Liabilities	$32.1M	↑ 5.09%

	Q2 FY23	Q/Q Change
Total Assets	$352.5M	↑ 44.46%
Total Liabilities	$725.3M	↑ 2753.79%

	Q3 FY23	Q/Q Change
Total Assets	$361.6M	↑ 2.58%
Total Liabilities	$31.7M	↓ 95.63%

	Q4 FY23	Q/Q Change
Total Assets	$339.9M	↓ 6.01%
Total Liabilities	$32.1M	↑ 1.21%

	Q1 FY24	Q/Q Change
Total Assets	$629.9M	↑ 85.32%
Total Liabilities	$29.3M	↓ 8.54%

	Q2 FY24	Q/Q Change
Total Assets	$620.1M	↓ 1.55%
Total Liabilities	$31.8M	↑ 8.37%

	Q3 FY24	Q/Q Change
Total Assets	$604.0M	↓ 2.59%
Total Liabilities	$51.1M	↑ 60.75%

	FY18	Y/Y Change
Operating Cash Flow	$-16.3M	↓ 297.3%
Investing Cash Flow	$-414.0K	↓ 105.39%
Financing Cash Flow	$84.6M	↑ 528506.25%

	FY19	Y/Y Change
Operating Cash Flow	$-36.7M	↑ 125.89%
Investing Cash Flow	$-3.2M	↑ 673.67%
Financing Cash Flow	$-2.2M	↓ 102.6%

	FY20	Y/Y Change
Operating Cash Flow	$-50.9M	↑ 38.68%
Investing Cash Flow	$-1000.0K	↓ 68.78%
Financing Cash Flow	$279.0M	↓ 12809.93%

	FY21	Y/Y Change
Operating Cash Flow	$-69.1M	↑ 35.8%
Investing Cash Flow	$-172.7M	↑ 17168.0%
Financing Cash Flow	$118.1M	↓ 57.67%

	FY22	Y/Y Change
Operating Cash Flow	$-86.7M	↑ 25.39%
Investing Cash Flow	$-17.1M	↓ 90.13%
Financing Cash Flow	$3.1M	↓ 97.39%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-22.1M	↓ 20.93%
Investing Cash Flow	$49.3M	↑ 14.28%
Financing Cash Flow	$130.5M	↑ 1087.18%

4d Molecular Therapeutics Inc Technicals Summary

Sell

Neutral

Buy

4d Molecular Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

4d Molecular Therapeutics Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
4d Molecular Therapeutics Inc	-15.49%	-70.72%	-52.7%	-69.73%	-83.16%
Regeneron Pharmaceuticals, Inc.	-7.0%	-24.01%	-9.49%	16.32%	106.34%
Biontech Se	9.3%	20.28%	18.26%	-57.29%	298.26%
Alnylam Pharmaceuticals, Inc.	-10.01%	60.97%	47.33%	35.08%	108.78%
Vertex Pharmaceuticals Incorporated	-8.33%	-4.49%	29.09%	120.96%	108.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
4d Molecular Therapeutics Inc	NA	NA	NA	-2.92	-0.24	-0.17	NA	7.15
Regeneron Pharmaceuticals, Inc.	18.56	18.56	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
4d Molecular Therapeutics Inc	Buy	$330.1M	-83.16%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$82.9B	106.34%	18.56	33.61%
Biontech Se	Buy	$28.5B	298.26%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	108.78%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$118.4B	108.53%	32.84	-4.51%

About 4d Molecular Therapeutics Inc

the mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim

Organization	4d Molecular Therapeutics Inc
Employees	147
CEO	Dr. John F. Milligan Ph.D.
Industry	Healthcare

Management People of 4d Molecular Therapeutics Inc

Name	Title
Dr. John F. Milligan Ph.D.	Executive Chairman
Dr. David H. Kirn M.D.	Co-Founder, CEO & Director
Dr. Fariborz Kamal Ph.D.	President & COO
Dr. Noriyuki Kasahara M.D., Ph.D.	Chief Scientific Officer
Dr. Robert Y. Kim M.B.A., M.D.	Chief Medical Officer
Ms. Theresa Janke	Co-Founder & Chief of Staff
Mr. Uneek Mehra	Chief Financial & Business Officer
Dr. Scott P. Bizily J.D., Ph.D.	Chief Legal Officer & Corporate Secretary
Dr. An Song Ph.D.	Chief Development Officer
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.	Senior VP & Therapeutic Area Head of Pulmonology

Important FAQs about investing in 4d Molecular Therapeutics Inc from India :

What is 4d Molecular Therapeutics Inc share price today?

4d Molecular Therapeutics Inc (FDMT) share price today is $7.18.

Can Indians buy 4d Molecular Therapeutics Inc shares?

Yes, Indians can invest in the 4d Molecular Therapeutics Inc (FDMT) from India.

With INDmoney, you can buy 4d Molecular Therapeutics Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy 4d Molecular Therapeutics Inc at zero transaction cost.

How can I buy 4d Molecular Therapeutics Inc shares from India?

It is very easy to buy 4d Molecular Therapeutics Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of 4d Molecular Therapeutics Inc be purchased?

Yes, you can buy fractional shares of 4d Molecular Therapeutics Inc with INDmoney app.

What are the documents required to start investing in 4d Molecular Therapeutics Inc stocks?

To start investing in 4d Molecular Therapeutics Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.